Authors
Latest:
Exploring Current and Upcoming Therapies for Hepatocellular CarcinomaDavid J. Pinato, MD, PhD, discusses past and current trials that are significant for the hepatocellular carcinoma patient population.
Latest:
Dr. Stewart on the Impact of Delaying Approval on Overall SurvivalDavid J. Stewart, MD, head, Division of Medical Oncology, University of Ottawa/The Ottawa Hospital, discusses a study that investigated the impact of delaying approval on overall survival.
Latest:
Updated ECHELON-1 Findings Demonstrate Potential Toxicities of Brentuximab Vedotin Combo in cHLDavid J. Straus, MD, discusses the toxicities associated with the combination of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with stage III/IV classical Hodgkin lymphoma, according to data from the 3-year update of the ECHELON-1 trial presented at the 2019 ASCO Annual Meeting.
Latest:
The Need to Study Tissue BiomarkersDavid L. Rimm MD, PhD, from Yale School of Medicine, discusses the need for further research into tissue biomarkers in breast cancer.
Latest:
tttPharmacist Glycemic Control Team Associated With Improved Perioperative Glycemic and Utilization OutcomesImplementation of a pharmacist-led glycemic control team was associated with improved glycemic control and utilization outcomes in a population of noncritically ill surgical patients.
Latest:
Recognizing Immunotherapy Side Effects in the Community SettingDavid M. Nanus, MD, chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine, discusses the use of immunotherapy in the community setting. He also gives advice to community oncologists that are using these treatments in their practice. <br />
Latest:
Expert Addresses Major Challenge in Treatment of MyelomaDavid M. Siegel, MD, PhD, discusses one of the biggest dilemmas to arise recently in the treatment of multiple myeloma.
Latest:
How CAR T Cells Can Change the Treatment Landscape for Non-Hodgkin LymphomaDavid Maloney, MD, PhD, medical director, Cellular Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center, discusses the results of the ZUMA trial and how chimeric antigen receptor CAR T-cell therapy is changing the treatment landscape for non-Hodgkin lymphoma.
Latest:
KTE-X19 Shows Efficacy as Treatment of MCL in the ZUMA-2 TrialDavid Miklos, MD, PhD, explains the rationale behind the ZUMA-2 trial of KTE-X19 as well as the efficacy of the drug.
Latest:
CAR T-Cell Therapy Appears Promising in Relapsed/Refractory DLBCLDavid Miklos, MD, discusses exciting data for the use of chimeric antigen receptor T-cell therapy as treatment of patients with diffuse large B-cell lymphoma.
Latest:
Managing Known CAR T-Cell Toxicities With KTE-X19David Miklos, MD, PhD, describes the toxicity profile of KTE-X19, a chimeric antigen receptor T-cell therapy, in the ZUMA-2 trial.
Latest:
Long Duration of Response Seen for Pembrolizumab in Endometrial CancerDavid O’Malley, MD, discusses the background and updated results of the KEYNOTE-158 trial looking at pembrolizumab monotherapy in patients with advanced endometrial cancer.
Latest:
The Accuracy and Availability of Genetic Testing for Lung CancerDavid P. Carbone, MD, PhD, describes variations in the accuracy and availability of genetic testing technologies for patients with lung cancer.
Latest:
How Physicians Can Detect ctDNA in MelanomaDavid Polsky, MD, PhD, discusses methods to identify circulating tumor DNA in patients with melanoma.
Latest:
Gandara Reviews Chemotherapy and Immunotherapy for NSCLC Based on StageAn otherwise healthy 60-year-old White woman presented with a nonproductive cough. She was was later diagnosed with NSCLC.
Latest:
Interim Analysis Demonstrates Reassuring Toxicity Profile for GlioblastomaDavid Reardon, MD, discusses the interim results and toxicity with INO-5401 and INO-9012 delivered intramuscularly with electroporation in combination with cemiplimab in patients with newly diagnosed glioblastoma.
Latest:
Neoadjuvant Durvalumab Shows Benefit in Triple-Negative Breast CancerDavid Rimm, MD, PhD, discusses the key takeaways from the results of a phase I/II trial presented in a poster at the 2019 San Antonio Breast Cancer Symposium, which evaluated neoadjuvant checkpoint inhibition in a small subset of patients with triple-negative breast cancer.<br />
Latest:
Hong Discusses Patients Who Benefit From LarotrectinibDavid S. Hong, MD, discusses which disease subgroups may benefit from treatment with larotrectinib.
Latest:
The Impact of Neuroendocrine Tumor Heterogeneity During Disease ProgressionDavid S. Klimstra, MD, discusses the impact of tumor heterogeneity during disease progression. This was the topic of a talk given by Oliver G. McDonald, MD, PhD, at the 2014 NANETS Symposium.
Latest:
Innovative Research in Myeloma Treatment: Insights From Dr. SiegelDavid Samuel Dicapua Siegel, MD, shared his perspectives on promising areas of research that could advance the care of patients with myeloma.
Latest:
Ruxolitinib Used to Prevent GVHD Throughout Stem Cell TransplantationDavid S. Snyder, MD, discusses using ruxolitinib to prevent patients receiving stem cell transplantation from developing graft versus host disease.
Latest:
Sallman on Eprenetapopt and Azacitidine in TP53-Mutant MDS/AMLDavid Sallman, MD, discusses using eprenetapopt and azacitidine in TP53-mutant myelodysplastic syndrome and acute myeloid leukemia post-allogeneic stem cell transplantation.
Latest:
ADRIATIC Trial: Durvalumab Redefines Limited-Stage SCLC TreatmentDavid Spigel, MD, discusses the significant benefits of durvalumab as consolidation therapy following standard chemoradiotherapy for patients with limited-stage small cell lung cancer.
Latest:
Dr. David Steensma on Midostaurin and its Future Uses in Acute LeukemiaDavid Steensma, MD, discusses how midostaurin could affect the treatment paradigm for acute leukemia. He says that while midostaurin is not currently approved by the FDA, studies show its potential usefulness when added to conventional induction platforms.
Latest:
Genomic Features of SarcomaDavid Thomas, FRACP, PhD, director and division head, Genomic Cancer Medicine, Cancer Division, Garvan Institute of Medical Research, discusses the genomic features of sarcoma and how they factor into the treatment landscape of this disease.
Latest:
Chemotherapy-Induced Peripheral Neuropathy in Breast CancerDawn Hershman, MD, MS, medical oncologist, Columbia University Medical Center, discusses chemotherapy-induced peripheral neuropathy in breast cancer.
Latest:
The Changing Landscape of Oncology: Impact for Payers and ProvidersCancer strikes fear as a clinical diagnosis. It also keeps employer medical directors up at night, wondering what the future will bring in the context of the limited dollars available for all medical care and diseases.
Latest:
The Future of Surgery and Targeted TherapiesDeanna J. Attai, MD, discusses the future of surgery and targeted therapies in the treatment of breast cancer.
Latest:
New Metastatic Cervical Cancer Treatments Give HopeInvestigators treating patients with gynecologic malignancies are optimistic that multiple clinical trials exploring new second-line cervical cancer treatments will result in a much-anticipated breakthrough for the field.
